KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Q3 2025 value amounting to $356.6 million.

  • Acadia Pharmaceuticals' Total Current Liabilities rose 367.47% to $356.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $356.6 million, marking a year-over-year increase of 367.47%. This contributed to the annual value of $394.9 million for FY2024, which is 5530.53% up from last year.
  • Acadia Pharmaceuticals' Total Current Liabilities amounted to $356.6 million in Q3 2025, which was up 367.47% from $330.0 million recorded in Q2 2025.
  • In the past 5 years, Acadia Pharmaceuticals' Total Current Liabilities ranged from a high of $394.9 million in Q4 2024 and a low of $88.2 million during Q3 2021
  • In the last 5 years, Acadia Pharmaceuticals' Total Current Liabilities had a median value of $209.6 million in 2023 and averaged $217.9 million.
  • Per our database at Business Quant, Acadia Pharmaceuticals' Total Current Liabilities tumbled by 934.16% in 2021 and then skyrocketed by 10238.32% in 2023.
  • Acadia Pharmaceuticals' Total Current Liabilities (Quarter) stood at $96.1 million in 2021, then soared by 30.77% to $125.6 million in 2022, then surged by 102.38% to $254.3 million in 2023, then skyrocketed by 55.31% to $394.9 million in 2024, then dropped by 9.7% to $356.6 million in 2025.
  • Its Total Current Liabilities stands at $356.6 million for Q3 2025, versus $330.0 million for Q2 2025 and $302.5 million for Q1 2025.